Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive into the world of biotech with fresh insights, sharp analysis, and the stories that are shaping the future of health. Whether you’re an industry insider, an investor, or just biotech-curious, we’ve got something for you.
We are now publishing 7x per week according to the following cadence:
Mondays: Stock Analysis & Biotech Catalysts
Tuesdays: Biotech hot topics (X-article)
Wednesdays: Podcast
Thursdays: Public & Private Biotech Markets
Fridays: Your Weekly Biotech Fix
Saturdays: Podcast
Sundays: Biotech Strategic Topics
We are also publishing unique content on X - be sure to follow up if you are not already @BowTiedBiotech. And to check-out the archive of our work on X you can find it on our website at: BowtiedBiotech.subtack.com/x-articles.
SUBSCRIBE TO PODCAST HERE:
Please help spread the work by subscribing and hitting the share button if you are enjoying content!
Welcome to the Bowtied Biotech Podcast! Today, we're diving into one of the most transformative trends in the global pharmaceutical industry: the growing collaboration between U.S. biopharma companies and China's innovative biotech sector. Despite geopolitical tensions, the remarkable science emerging from China has captured the attention of venture capitalists and pharmaceutical giants alike. From groundbreaking licensing deals to bold clinical trial strategies, we'll explore how companies like Summit Therapeutics and Akeso Biopharma are redefining the rules of engagement. Join us as we unpack the opportunities, challenges, and future of this exciting new era of global collaboration in drug development.
📣🎙️ TODAY’S POCAST:
( 0:07 ) Welcome to the BowtiedBiotech Podcast
( 0:28 ) U.S. Biopharma Looks to China
( 1:06 ) Licensing Deals in Obesity and Oncology
( 2:29 ) Summit-Akeso’s Bold Collaboration
( 3:47 ) Akeso’s Keytruda Trials in China
( 5:43 ) Benefits of Licensing Models
( 6:16 ) Faster Clinical Trials in China
( 7:03 ) Challenges: IP and Geopolitics
( 8:39 ) BioSecure Act and Collaboration
(10:25 ) Conclusion: Future of U.S.-China Biopharma
CONCLUSION
We hope you are enjoying our first leap into the podcast world! Instead of waiting until everything is perfect, we’re diving in and will continue improving as we go. Feel free to send us your suggestions, feedback, or constructive criticism—we’d love to hear from you!
As a reminder, if looking to go deeper into the topics we cover check out our website BowTiedBiotech.com, or DM us on twitter, or email us: bowtiedbiotech@gmail.com
ABOUT BOWTIEDBIOTECH
As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients. Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.
DISCLAIMER
None of this is to be deemed legal or financial advice of any kind. All updates are sourced from publicly available disclosures. Insights are *opinions* written by an anonymous cartoon/scientist/investor.
TOP BOWTIEDBIOTECH NEWSLETTERS
Share this post